Annovis Bio, Inc 8-K, filed Oct 20, 2026
Annovis Bio, Inc. (ANVS)
About this 8-K
Annovis Bio, Inc filed this 8-K on October 20, 2026, reporting on events of October 19, 2026.
Annovis Bio, Inc. corrected audit-fee disclosure for Ernst & Young LLP, reporting total fees of $515,000 for 2025 and $482,045 for 2024. AI summary
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date
of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices, and Zip Code)
(
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 8.01 | Other Events |
Due to a typographical error in the Company’s proxy statement for its annual meeting of stockholders held on June 17, 2026, the Company is filing this Current Report on Form 8-K to correct the disclosure of audit fees. The corrected fees are as follows:
| Fee Category: | 2025 (Ernst & Young LLP) | 2024 (Ernst & Young LLP) |
| Audit Fees: | $415,000 | $375,000 |
| Audit-Related Fees: | $100,000 | $107,045 |
| Tax Fees: | -- | -- |
| All Other Fees: | -- | -- |
| Total Fees: | $515,000 | $482,045 |
| Item 9.01 | Financial Statements and Exhibits |
| Exhibit Number |
Description | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ANNOVIS BIO, INC. | ||
| Date: October 19, 2026 | ||
| By: | /s/ Maria Maccecchini | |
| Name: Maria Maccecchini | ||
| Title: Chief Executive Officer | ||